Consequences of Lipid Droplet Coat Protein Downregulation in Liver Cells
Abnormal Lipid Droplet Metabolism and Induction of Insulin Resistance

Ming Bell,1 Hong Wang,1 Hui Chen,2 John C. McLenithan,3 Da-Wei Gong,3 Rong-Zee Yang,3 Daozhan Yu,3 Susan K. Fried,3 Michael J. Quon,2 Constantine Londos,4 and Carole Sztalryd1

OBJECTIVE—Accumulation of intracellular lipid droplets (LDs) in non-adipose tissues is recognized as a strong prognostic factor for the development of insulin resistance in obesity. LDs are coated with perilipin, adipose differentiation–related protein, tail interacting protein of 47 kDa (PAT) proteins that are thought to regulate LD turnover by modulating lipolysis. Our hypothesis is that PAT proteins modulate LD metabolism and therefore insulin resistance.

RESEARCH DESIGN AND METHODS—We used a cell culture model (murine AML12 loaded with oleic acid) and small interfering RNA to directly assess the impact of PAT proteins on LD accumulation, lipid metabolism, and insulin action. PAT proteins associated with excess fat deposited in livers of diet-induced obese (DIO) mice were also measured.

RESULTS—Cells lacking PAT proteins exhibited a dramatic increase in LD number and a decrease in LD number. Further, the lipolytic rate increased by 2- to 2.5-fold in association with increased adipose triglyceride lipase (ATGL) at the LD surface. Downregulation of PAT proteins also produced insulin resistance, as indicated by decreased insulin stimulation of Akt phosphorylation (P < 0.001). Phosphoinositide-dependent kinase-1 and phosphoinositide 3-kinase decreased, and insulin receptor substrate-1 307 phosphorylation increased. Increased lipids in DIO mice livers were accompanied by changes in PAT composition but also increased ATGL, suggesting a relative PAT deficiency.

CONCLUSIONS—These data establish an important role for PAT proteins as surfactant at the LD surface, packaging lipids in smaller units and restricting access of lipases and thus preventing insulin resistance. We suggest that a deficiency of PAT proteins relative to the quantity of ectopic fat could contribute to cellular dysfunction in obesity and type 2 diabetes. Diabetes 57:2037–2045, 2008

The surge in obesity predicts a further increase in associated complications, insulin resistance, diabetes, and heart disease (1,2). Increased fatty acid availability in obesity is associated with accumulation of ectopic fat, mainly in the form of triacylglycerol (TAG) (3). Although ectopic fat correlates with systemic and tissue insulin resistance (4–6), a number of circumstances are known in which high tissue lipid stores are not associated with insulin resistance. Endurance-trained athletes have high intramyocellular lipids yet are highly insulin sensitive. Importantly, the size and intracellular distribution of lipid droplets (LDs) differs in muscle and adipose tissues.

LDs are energy-storage organelles but have a surprisingly complex function in lipid homeostasis. LD biogenesis is a fundamental cellular function; when exposed to nonesterified fatty acids (NEFAs), cells store them as TAG in LDs (8). Such LD accumulation maintains low intracellular NEFAs, avoiding their toxic effects on cellular physiology while supporting cellular needs by releasing NEFAs for use in β-oxidation and membrane synthesis. LDs’ function to sequester and release NEFAs is thus critical for proper cellular function. Nonadipogenic tissues in patients with metabolic syndrome are exposed to chronically elevated serum levels of NEFAs, and these tissues respond by LD accumulation. Such ectopic fat deposition protects from NEFA-mediated lipotoxicity (9), but in patients with metabolic syndrome the LD is inadequate to prevent pathological consequences. An important question arises: what molecular mechanisms regulate lipid storage in nonadipogenic tissues?

To date, we have only limited information on nonadipose LDs. Recent studies (10,11) identified a proteomic “signature,” consistently including at least one member of the PAT protein family: perilipin, adipose differentiation–related protein (ADFP), tail interacting protein of 47 kDa (Tip47), S3–12, and lipid dosage droplet protein-5 (LSDP-5). Despite tissue dependence, the ubiquitous nature of the family suggests an important role in LD machinery. ADFP, Tip47, and LSDP-5 are broadly distributed, notably in nonadipogenic liver and muscle tissues that do not express perilipin (13,24). Our hypothesis is that saturation of nonadipogenic tissue’s capacity to appropriately regulate storage and release of NEFAs via LDs results from varia-
tions in the expression and/or activity of PAT proteins. To study functional consequences of downregulating two major PAT proteins, ADFP and Tip47, on insulin resistance and lipid metabolism, we used small interfering RNA (siRNA) in a cell culture model. To assess the in vivo relevance of this finding, we measured the expression of PAT proteins associated with excess lipids accumulated in the livers of high-fat–fed obese mice.

**RESEARCH DESIGN AND METHODS**

**Cell culture.** AML12 cells (Dr. Steven Farmer, Boston University, Boston, MA) were grown with the standard protocol (American Type Culture Collection, Manassas, VA). For siRNA experiments, cells were plated in 24 multiwell dishes (Costar; Thermo Fisher Scientific, Pittsburgh, PA) at a density of 1 × 10^4 cells per well, transfected the next day with Hyperfect (Qiagen, Valencia, CA) according to the manufacturer's instructions. For immunocytochemistry, cells were plated in four-well chamber slides (Labtek; Thermo Fisher Scientific). For insulin-signaling assays, cells were deprived of insulin for 24 h and for the last 12 h were incubated in Dulbecco's modified Eagle's medium (DMEM)/F-12 media (1:1) containing 1% defatted BSA (Sigma-Aldrich, St. Louis, MO) and supplemented with 400 μmol/l oleic acid complexed to 0.4% BSA to promote TAG deposition. The next day, cells were incubated in DMEM/F-12 media (1:1) containing 1% defatted BSA (Sigma-Aldrich) for 9 h before a 10-min incubation with insulin at the concentration indicated. Cells were harvested in cold lysis buffer (150 mmol/l NaCl; 50 mmol/l Tris-HCl, pH 7.5; 1% Triton X-100; 0.5% NP-40; 0.25% sodium deoxycholate; 1 mmol/l EDTA; 1 mmol/l EGTA; 0.2 mmol/l ortho-vanadate; 1 mmol/l NaF; and protease inhibitor cocktail) (Roche Applied Science, Indianapolis, IN).

**Oligos.** siRNA was purchased from Qiagen (HP-quantarized siRNA). Positive siRNA for map kinase 1 and fluorescent oligos (Qiagen) were used to establish efficient conditions for transfection to obtain 80% inhibition by Western blot (12) versus All Star negative control. For off-target toxicity, we used siRNA negative for insulin signaling: a negative siRNA targeting ADFP with a two-base mismatch (Ctl1), sense sequence 5'-AACGTCGTGCAGCAAAGAAGAA-3' (online appendix Fig. S-9 [available at http://dx.doi.org/10.2337/db07-1383]); and a negative -siRNA targeting Tip47 (Ctl2), sense sequence 5'-GC GUGUCCCAUCUGAC-3' (12). Sequence responses for Tip47 (5'-AACAGCAC AGGAAAGAGGAG-3') and ADFP (5'-AACGTGTCGTGCAGCAAAGAAGAA-3') were selected by potency. Total siRNA per well was 10 nmol/l for all transfections; for double transfection using one-third Tip47 and two-thirds ADFP siRNA; for triple using one-fourth Tip47, one-half ADFP, and one-fourth adipose triglyceride lipase (ATGL) siRNA; and for downregulation confirmed (online appendix Figs. S-4 and -7). siRNA for ATGL was reported (35) and confirmed by immunoblot (Fig. S-3). siRNA efficiencies were quantified by Western blot (Un-sc; Silk Scientific, Orem, UT) and results expressed as percentage of control.

**Lipid extraction and thin-layer chromatography.** Cell monolayer was washed with ice-cold PBS and scraped into 1 ml PBS. For total TAG, lipids were extracted by the Dole method (40) from five wells of a 24-well dish. The total upper phase was dried down, resuspended in isopropanol, and assayed with a triglyceride kit (Wako Chemicals, Richmond, VA). Protein was measured by a kit (Pierce Biotechnology, Rockford, IL). For triglyceride synthesis, lipids were extracted by the Bligh-Dyer method (41) and 10% of the total lipids were analyzed with thin-layer chromatography extractions performed as reported (37,38) (see online appendix). Intracellular diacylglycerol, NEFAs, and ceramide were measured by analytical service (Avanti Polar Lipids, Albaster, AL) (43).

**Glucose output.** Measurements were performed according to Berus et al. (48). Briefly, 2 days following siRNA transfection, cells were incubated in DMEM/F-12 medium containing 1% BSA, 1 mmol/l L-glutamine, 1 mmol/l pyruvate, and 20 mmol/l lactate containing dexamethasone (Sigma-Aldrich), and 1 μmol/l CAMP (EMD Chemicals, Gibbstown, NJ) for 24 h. Cells were incubated in 0.35 ml (per well) of phenol red-free, glucose-free DMEM containing 2 mmol/l pyruvate and 20 mmol/l lactate containing dexamethasone and CAMP. Some wells also contained insulin (10 μmol/l concentration). Media was collected 5 h later for glucose measurement (48) with a fluorometer (Molecular Devices, Union City, CA) in triplicate. Glucose output rate was normalized by cellular protein concentration and expressed as nanomols of glucose per milligram of protein every 5 h. Two separate experiments were performed.

**Fat cake preparation.** Four 24-well dishes for each condition were treated with siRNA negative or ADGF and Tip47. LD isolation was as reported (25). Total homogenate protein was determined and adjusted to 1 μg/ml. The lipid fat cake was isolated and suspended in 200 μl PBS containing 5% SDS.

**Statistical analysis.** Statistical significance was by one-way ANOVA or two-tailed Student's t test. (GraphPad software, San Diego, CA).

**RESULTS**

**AML12 cell LDs contain mostly ADFP at the surface.** After incubation of AML12 liver cells with 400 μmol/l oleic acid, numerous LDs appear, and most are coated with ADFP and Tip47 (Fig. 1A). ADFP and fewer with Tip47 (Fig. 1A). ADFP and Tip47 were found exclusively at LD surfaces, while Tip47 was found in both cytosolic and LD compartments. Other PAT proteins were not detected by immunocytochemistry or immunoblot (results not shown). Hence, AML12 cells express two PAT proteins, ADFP and Tip47.

**PAT protein downregulation induces change in LD morphology and surface profile.** The effect from downregulation of Tip47, ADFP, or both with siRNA are shown in Fig. 1B and C. siRNA transfection produced minimal cellular toxicity from unchanged levels of β-actin. Efficiency of Tip47 inhibition was >95%, and efficiency of ADFP inhibition was 80%. siRNA treatments effectively produced droplets coated with only one of two PAT proteins or none (Fig. 1B). ADFP downregulation led to a dramatic increase in Tip47 protein at the LD surface, although total Tip47 protein in homogenates was not affected by increased exogenous oleic acid (online appendix Fig. S-1). Thus, increased Tip47 at the LD surface is...
recruited from preexisting cytosolic Tip47. Behavior of PAT proteins in control cell homogenates in response to increased exogenous NEFAs is also different (online appendix Fig. S-1); while ADFP increased proportionally to the exogenous lipid, Tip47 was barely affected. Importantly, knockdown of one or more PAT proteins resulted in substantial changes in LD size and number, as observed by bodipy staining (Fig. 2) (online appendix Figs. S-5A–D and S-7), phase contrast microscopy (online appendix Fig. S-2), or quantify (Fig. 3). Absence of PAT proteins induced a marked increase in LD size and decrease in LD number (28 ± 2.6 vs. 48.09 ± 6.06 for control; P < 0.05). When Tip47 was predominant, the LD morphology appeared similar to control treatment cells. When ADFP was predominant, LD number increased (251.7 ± 22.6 vs. 48.09 ± 6.06 for control; P < 0.01) but LD size was smaller. Despite changes in LD morphology, TAG content in cellular extracts of oleic acid–loaded cells was unchanged (Fig. 4B). However, total TAG decreased in PAT protein–deprived cells when grown without oleic loading. (Fig. 4A). This difference prompted examination of PAT protein effects on lipid metabolism.

**Metabolic consequences of altered PAT protein profiles**

**Lipid metabolism.** In cells lacking either ADFP or Tip47, no significant alteration in lipolysis was observed (Fig. 5A). However, lipolysis significantly increased up to two-fold (Fig. 5A) (one-way ANOVA; P < 0.02) in AML12 cells lacking both proteins. A recent phenotype reported for ATGL-null mice suggests that ATGL is operative in liver (14). Presence of ATGL in AML12 cells was revealed by ATGL-targeted siRNA treatment (online appendix Fig. S-3), which increased LD, as expected from decreased lipolytic activity from loss of ATGL. In cells lacking PAT proteins, ATGL increased at the LD surface (Fig. 5B) (online appendix Fig. S-4). Immunoblot analysis revealed an increase in both ATGL and CGI-58 in fat cakes from these cells (Fig. 5C). CGI-58 is known to increase ATGL

---

**FIG. 1. Identification and downregulation of all PAT proteins (ADFP and Tip47) in AML12 cells.** A: Cells were incubated with 400 μmol/l oleic acid for 12 h before staining. Cells were costained with a polyclonal goat anti-ADFP antibody and with a rabbit polyclonal anti-Tip47 antibody and, respectively, alexa fluor 488– or 594–conjugated secondary antibodies. Fluorescent and phase images were generated by an LSM 510 confocal laser microscope. Bar represents 50 μm. B: Coimmunostaining with ADFP and Tip47 of AML12 cells treated for 4 days with siRNA ADFP, siRNA Tip47, both combined, or control. Cells were treated as above. C: Immunoblots of total cellular protein extract from AML12 cells treated with control siRNA (Qiagen) (lane 1); siRNA ADFP (lane 2); siRNA Tip47 (lane 3); or both combined (lane 4). Rabbit polyclonal anti-Tip47, anti-ADFP, and anti-β-actin antibodies were used as loading control. (Please see http://dx.doi.org/10.2337/db07-1383 for a high-quality digital representation of this figure.)

---
activity and to interact with PAT proteins (30). Increase of ATGL at LDs in cells lacking ADFP and Tip47 supports the hypothesis that these proteins limit access of endogenous lipase to the LDs. In contrast, lack of PAT proteins did not affect uptake of 3H exogenous oleic acid and had little influence on the ability of cells to utilize exogenous NEFAs for TAG or phospholipid synthesis (online appendix Fig. S-4). High-performance liquid chromatography analysis did not reveal significant differences in the intracellular content of diacylglycerol (1.45 ± 0.25% [wt/wt] for Ctl vs. 1.4 ± 0.2% [wt/wt]) for cells lacking PAT proteins or ceramide (1.1% in both conditions), but 1.25% (wt/wt) intracellular NEFAs were found in cells lacking PAT proteins, while NEFAs remain undetected in control cells (n = 2 experiments).

**Insulin signaling.** Because dysregulation of cellular lipid metabolism has been linked to insulin resistance, we measured the effect of PAT siRNA treatment on insulin activation of protein kinase B (Akt) in AML12 cells by immunoblot analysis of cellular protein extracts using phosphospecific antibodies. In both control- and siRNA-treated cells, insulin stimulated phosphorylation Akt phos-

**FIG. 2.** Morphological differences in AML12 cells following downregulation of PAT proteins. Cells were stained with bodipy f568, which preferentially stained neutral lipid. Fluorescent and phase images were generated by a LSM 510 confocal laser microscopy. Bar represents 50 μm. (Please see http://dx.doi.org/10.2337/db07-1383 for a high-quality digital representation of this figure.)

**FIG. 3.** Composition of the PAT proteins affects the LD size distribution. Number and diameter of LDs were measured following imaging cells treated with siRNA control (Ctl) (Qiagen) (□), both siRNAs Tip47 and ADFP (Both) (■), siRNA ADFP (□), and siRNA Tip47 (□). Data are means ± SE from 11 separate experiments for control and ADFP, from three separate experiments for Tip47, and from 27 separate experiments for both. ***P < 0.0001; *P < 0.05 vs. control (t test).

**FIG. 4.** Absence of exogenous NEFA reveals differences in accumulating lipids in cells lacking ADFP and Tip47. A: Triglycerides were measured in cells grown in culture media treated with siRNA control (Qiagen) (□), both siRNAs Tip47 and ADFP (■), siRNA ADFP (□), and siRNA Tip47 (□). B: Triglycerides were measured in cells grown in culture media supplemented overnight with 400 μmol/l of oleic acid in cells treated as described above. Data are means ± SE from three separate experiments and *P < 0.001 (one-way ANOVA) for cells lacking both ADFP and Tip47 grown without exogenous NEFA addition.
DISCUSSION

Using siRNA technology, we were able to develop evidence supporting the role of the PAT proteins in the regulation of ectopic fat deposition and demonstrate the importance of defected LD utilization in the development of cellular insulin resistance. First, the composition of PAT proteins at the LD surface dictates their size and number. Second, the affinity of ADFP may be greater than Tip47 for fatty acids (18). Upon insulin stimulation, cells lacking PAT proteins also increased PKC-ε protein and phosphorylation in the total cellular membrane fraction (Fig. 6D). ERK1/2 phosphorylation was increased in both basal and stimulated conditions in cells lacking PAT proteins (Fig. 7G). Overall glucose output was very low in AML12 cells; however, 10^{-8} mol/l insulin was able to suppress glucose output in cells transfected with control siRNA to a greater extent than in cells lacking ADFP and Tip47, confirming a defect in these latter cells in insulin signaling (online appendix Table 1).

In vivo studies. Lack of information on PAT protein and lipase content of liver fat cake in established models of insulin resistance prompted an examination of DIO mice. Liver fat cakes isolated from DIO mice have fourfold-increased lipid content (11.7 ± 2.3% [wt/wt] vs. 3.4 ± 1% [wt/wt]) for ad libitum–fed mice (P < 0.05). Importantly, ATGL content also increased (Fig. 8). Despite the large increase in lipids, a matching increase was observed only for LSPD-5, while a significant change in Tip47 was not found and the increase in ADFP appears modest.

phorylation at Ser473, an effect previously shown to correlate with the extent of Akt activation in hepatocytes (16). However, absence of PAT proteins resulted in a significant decrease in insulin responsiveness and sensitivity compared with the control (Fig. 6A and B). Akt phosphorylation was not affected when only one PAT protein was downregulated (results not shown). Effect on Akt phosphorylation was also observed with decreasing concentration of oleic acid in media (online appendix Fig. S-8). To test if increased lipolysis contributed to the observed decrease in insulin responsiveness, cells lacking all PAT proteins were additionally treated with ATGL siRNA. Figure 6C shows that the triple inhibition normalized insulin stimulation of Akt to control levels. The total amount of Akt did not differ among the various treatments. Upstream regulation of Akt was also affected by lack of PAT proteins: phosphorylations of PDK-1 (Fig. 7A), IRS-1/phosphoinositide 3-kinase activity were decreased in cells lacking PAT proteins (Fig. 7B). IRS-1–Ser307 phosphorylation, which promotes general inhibition of IRS-1 signaling (17), was increased in cells lacking PAT proteins (Fig. 7C). However, this did not result in a detectable decrease in tyrosine phosphorylation of IRS-1 (results not shown). Downstream targets of Akt, Foxo-1, and GS3-Ku/β were affected (Fig. 7E and F). Activation of PKC-ε was previously shown to be involved in insulin resistance induced by fatty acids (18). Upon insulin stimulation, cells lacking PAT proteins also increased PKC-ε protein and phosphorylation in the total cellular membrane fraction (Fig. 6D). ERK1/2 phosphorylation was increased in both basal and stimulated conditions in cells lacking PAT proteins (Fig. 7G). Overall glucose output was very low in AML12 cells; however, 10^{-8} mol/l insulin was able to suppress glucose output in cells transfected with control siRNA to a greater extent than in cells lacking ADFP and Tip47, confirming a defect in these latter cells in insulin signaling (online appendix Table 1).
because such a system provides a model for one of the most important tissues where ectopic fat develops. The value of a loss-of-function approach for PAT proteins has been proven with the perilipin-null mice, which exhibit a lean phenotype and enable identification of its regulatory role of lipolysis (19,20). However, the ADFP-null mice exhibit few phenotypic alterations (22), attributed tentatively to a compensatory replacement by Tip47 (12). Further analyses of ADFP-null fibroblast cells treated with siRNA against Tip47 supported the importance of the PAT proteins’ role in lipid metabolism (12). AML12 cells are attractive for studies of LDs and insulin signaling (15,23).

Only two PAT proteins, ADFP and Tip47, were found in AML12 cells, predominately ADFP at the liver LD surface (25), whereas Tip47 was observed on some droplets but mainly in the cytosol. This corroborates previous findings that Tip47 and ADFP behave differently in most cells in that Tip47 can be present both in the cytosol and at the LD while ADFP is seen primarily at the LD upon lipid-loaded conditions (25). Inhibition of ADFP expression resulted in increased Tip47 at the LD surface in AML12 cells, similar to our earlier report with cells from ADFP-null mice, suggesting that ADFP has a greater affinity for LDs than Tip47. Thus, when ADFP expression is inhibited, Tip47 moves to the LD surface without major change in LD size and number. However, if Tip47 is repressed, ADFP is then the only PAT protein present and the LD number increases while the sizes decrease. This morphological change may reflect ADFP’s greater ability to bind to LDs and greater surfactant function. Finally, absence of both PAT proteins generated fewer but larger LDs. Since PAT proteins have surfactant properties, in their absence LDs probably fuse to minimize surface area contact with the surrounding aqueous cytosol. These studies demonstrate that the PAT protein composition in liver cells is a critical determinant of LD size and number.

Interestingly, varying the LD coat protein did not affect the ability of cells to take up exogenous NEFAs and to esterify it into TAG. Thus, ADFP and Tip47 are not important factors in determining the amount of TAG produced, but they are important factors in determining how it is packaged. However, without PAT proteins, TAG lipolysis increased, demonstrating a function of these two PAT proteins to inhibit LD hydrolysis by endogenous lipase(s). This property is a feature shared for most PAT proteins. Perilipin is known to regulate lipid storage in adipose cells (21,42), and published studies support that ADFP (34), Tip47 (12), and, recently, LSDP-5 (13) protect LD TAG against lipolysis.

Endogenous lipases in liver cells responsible for LD turnover have not yet been catalogued to the same extent as in adipose tissue (26). The phenotype of ATGL-null mice indicates that it may be an important lipase not only in adipose tissue but also in nonadipose tissue. Notably, hepatic fat content was doubled in ATGL-null mice compared with wild-type (14). Interestingly, by immunocytochemistry and immunoblot analysis, we found an ATGL increase at the LD surface when all PAT proteins were absent, confirming a recent report (44) that the lack of ADFP increases ATGL presence in fibroblasts. Furthermore, by downregulating ATGL expression, we could show an active role of ATGL in LD turnover, as judged by increased LDs in cells lacking this lipase. These results led us to hypothesize that ATGL is one of the enzymes participating in LD hydrolysis in liver cells and, importantly, that nonadipose tissue PAT proteins also have a role in inhibiting LD hydrolysis.

A recent finding on ATGL regulation is that this enzyme appears to require CGI-58 for full activity in cytosolic extracts (27). CGI-58 is a protein that when mutated or truncated has been found to be responsible for LD accumulation in most tissues (Chanarin-Dorfman syndrome) (28,29). Most recently, CGI-58 was identified to bind to Perilipin and ADFP (30,31). In our studies, fat cake extract from cells lacking PAT proteins was enriched in CGI-58 protein. This led us to hypothesize that common mechanisms exist among PAT proteins to regulate ATGL access to the LD surface, both in adipose and nonadipose tissues.

FIG. 6. Effect of lack of PAT proteins on Akt. A: Decreased insulin sensitivity and responsiveness in AML12 cells lacking both ADFP and Tip47, measured by Akt phosphorylation (left) and inhibition of lipolytic activity by ATGL siRNA (right), returns the Akt phosphorylation to control levels. AML12 cells were treated with siRNA control 1 (Ctl1) or combined siRNAs ADFP and Tip47 (Both) for 4 days or combined siRNAs ADFP, Tip47, and ATGL (Triple). Akt phosphorylation was determined in the whole-cell lysate by immunoblotting with rabbit polyclonal antibody against Akt or against an Akt phospho-specific antibody. A: left and right: Representative Western blots. B: An insulin dose-response curve was generated by quantifying Western blot–enhanced chemiluminescence signals, with the help of an image software analysis UN-scan-it (Silk Scientific). Each data point is expressed in arbitrary units and represents the average of calculated ratio of the amount of phosphorylated Akt versus the total amount of Akt protein. All experiments were repeated at least three times. Each bar represents means ± SE. □, Ctl1; ■, Both. *P < 0.02; **P < 0.01.
We found that PAT protein downregulation is sufficient to induce insulin resistance in liver cells. These results led us to conclude that the mechanism underlying the defect in insulin resistance in the absence of PAT proteins is due at least in part to an increase in lipolytic rate and/or uncoupling to NEFA utilization. Absence of PAT proteins at the LD surface facilitates access of endogenous triglyceride lipases such as ATGL to the TAG substrate, releasing NEFAs that in turn affect the signaling cascade at multiple levels. These findings support our working hypothesis that ADFP and Tip47 play important roles in the regulation of ectopic fat, similar to the key role of perilipin in adipose tissue, and that their function can explain at least partially the connection between ectopic fat and development of insulin resistance. If true, then alteration in the composition and/or activity of PAT proteins will result in dysfunc-

FIG. 7. Insulin signaling steps upstream and downstream from Akt are also perturbed in cells lacking both Tip47 and ADFP. AML12 cells were cultured as above. On the day of the experiment, cells were treated with no or 10⁻⁸ mol/l insulin for 15 min prior to being scraped. A: PDK-1 phosphorylation is decreased in AML12 cells lacking ADFP and Tip47. PDK-1 phosphorylation was determined in the whole-cell lysate by immunoblotting with rabbit polyclonal antibody against PDK-1 or against a PDK-1 phospho-specific antibody. B: Cellular extracts were immunoprecipitated with an anti-IRS-1 antibody, and phosphatidylinositol 3-kinase activity was measured. Results are means ± SE arbitrary units. *P < 0.05 vs. basal of each group, PIP3, and phosphatidylinositol 3,4,5-triphosphate. C: IRS-1 serine 307 phosphorylation was determined in the whole-cell lysate by immunoblotting with rabbit polyclonal antibody against IRS-1 or against an IRS-1 phospho–specific antibody (Upstate Cell Signaling Solutions). D: Activation of PKCθ in AML12 cells lacking both ADFP and Tip47. Activation of PKCθ was determined with phospho-specific antibodies to PKCθ (Thr538). Pellets were obtained by centrifuging the whole-cell lysate at 10,000 g. The experiment was repeated three times with consistent results. E: Activation of Foxo-1 in AML12 cells lacking both ADFP and Tip47. F: Activation of GSk3 kinase in AML12 cells lacking both ADFP and Tip47. G: Activation of ERK1/2 in AML12 cells lacking both ADFP and Tip47.
β-oxidation and is present in liver (46). Knowing the redundancy with the PAT protein family, LSDP-5 may be responsible for the apparent discrepancy existing between these in vivo results and cell culture (47). The presence of LSDP-5 in liver LDs brings another level of complexity to the regulation of LD utilization. To date, little knowledge exists of LD PAT protein composition in insulin resistance models. We show here that liver LDs from the DIO disease model differ in the ratio of PAT proteins at the LD surface and, importantly, that ATGL is increased at the LD surface. Since ATGL-null mice have increased insulin sensitivity, we hypothesize that defects increasing ATGL access to the lipid surface and/or activity will have the opposite effect (i.e., promote insulin resistance). Thus, we hypothesize that DIO alters liver lipid turnover, contributing to insulin resistance.

It is widely accepted that excessive free fatty acid–induced insulin resistance involves intramyocellular and intrahepatocellular accumulation of TAG, activation of several serine/threonine kinases, reduction in tyrosine phosphorylation of IRS-1/2, and impairment of IRS/phosphoinositide 3-kinase pathway (32) and ERK1/2 pathway (32). Attention has been given in the literature thus far to a failure of mitochondrial oxidative function, but little thought has been given to the failure of the LD compartment to appropriately store the excess NEFAs (34). The results from these studies indicate that defects in LD lipolysis/utilization contribute to loss of ability of nonadipose tissue to maintain NEFA homeostasis and thus are responsible for deleterious consequences observed in the signaling pathway. These defects likely occur in the function/activity of the PAT family LD surface proteins regulating lipolysis. Future research focusing on LD utilization and its regulation will provide us with important clues for understanding regulation of cellular energy homeostasis.

**ACKNOWLEDGMENTS**

This work was supported by a career development award (1-05-CD-17) from the American Diabetes Association (to C.S.); a grant from the National Institutes of Health (1RO1 DK 075017-01A2 to C.S.); the Geriatric Research, Education and Clinical Center, Baltimore Veterans Affairs Health Care Center; a grant from the Clinical Nutrition Research Unit of Maryland (DK072488 to S.K.F.); and Intramural Research Programs of the National Institute of Diabetes and Digestive and Kidney Diseases and the National Center for Complementary and Alternative Medicine, National Institutes of Health.

We thank Dr. M.C. Woodle for his constant help and support and Dr. A.K. Kimmel for his helpful criticisms.

**REFERENCES**

1. Meigs JB: Epidemiology of the metabolic syndrome. Am J Manag Care 8 (Suppl. 11):S283–S292, 2002
2. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 365:1415– 428, 2005
3. Shulman GI: cellular mechanisms of insulin resistance. J Clin Invest 106:171–176, 2000
4. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, Nicole CJ, Vinson C, Gonzalez FJ, Reitman ML: Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 278:34268 –34276; 2003
5. Pretkki M, Vischer S, Glennon MC, Regazzi R, Deeney JT, Corkey BE: Malonyl-CoA and long chain acyl-CoA esters as metabolic coupling factors in nutrient-induced insulin secretion. J Biol Chem 267:5802–5810, 1992
6. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, Saffitz JE,
12. Sztalryd C, Bell M, Lu X, Mertz P, Hickenbottom S, Chang BH, Chan L, Kandel ES, Hay N: The regulation and activities of the multifunctional protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome. Cell Metab 5:30490–30497, 2004

20. Tansey JT, Sztalryd C, Gruia-Gray J, Roush DL, Zee JV, Gavrilova O, Dalen KT, Ulven SM, Amtsen BM, Solaas K, Nebb HI: PPAR modulation of major clases of Xenopus phospholipids by high performance liquid chromatography with evaporative light scattering detection. J Lipid Res 48:2751–2761, 2007

28. Lefevre C, Jobard F, Caux F, Bouabdar B, Karaduman A, Heilig R, Lakhdar H, Wollenberg A, Verret J-L, Weissbach J, Ozucic M, Lathrop M, Prud’homme J-F, Fischer J: Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome. J Am Gen Med 69:1002–1012, 2001

31. Subramanian V, Sawamura D, Nomura Y, Sugawara M, Shimizu H: Truncation of CGI-58 protein causes malformation of lamellar granules resulting in ichthyosis in Dorfman-Chanarin syndrome. J Invest Dermatol 125:1029–1034, 2005

32. Yamaguchi T, Omatsu N, Matsushita S, Osumi T: CGI-58 interacts with perilipin and is localized to lipid droplets: possible involvement of CGI-58 in lipid localization in Chanarin-Dorfman syndrome. J Biol Chem 279:30490–30497, 2004

33. Schrauwen P, Hesselink JK: Oxidative capacity, lipidotoxicity, and mitochondrial damage in type 2 diabetes. Diabetes 53:1412–1417, 2004

34. Xu G, Sztalryd C, Lu X, Tansey J, Tan, Dorward H, Kimmel AR, Londos C: Post-translational regulation of adipose differentiation-related protein by the ubiquitin/proteasome pathway. J Biol Chem 280:42841–42847, 2005

35. Kershaw EE, Hamm JK, Verhaagen LA, Peroni O, Katic M, Flier JS: Adipose triglyceride lipase: function, regulation by insulin, and comparison with adiponutrin. Diabetes 56:1849–1857, 2007

36. Gao Z, Zhang X, Zuberi A, Hwang D, Quon MJ, Lefevre M, Ye-J: Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. J Mol Endocrinol 18:2024–2034, 2004

37. Sztalryd C, Levacher C, Picon L: Acceleration by triiodothyronine of perilipin and is localized to lipid droplets but not recycling of fatty acid into phospholipid: evidence for functionally separate pools of acyl-CoA. Biochim J 324:529–534, 1997

38. Tansey JT, Huml AM, Vogt R, Davis KE, Jones JM, Fraser KA, Brasaemle DL, Kimmel AR, Londos C: Functional studies on native and mutated forms of perilipins: a role in protein kinase A-mediated lipolysis of triacylglycerols. J Biol Chem 278:30490–30497, 2003

39. Tansey JT, Contreas JA, Kimmel AR, Londos C: Functional conservation for lipid storage droplet association of perilipin and is localized to lipid droplets. Diabetes 55:607–613, 2006

40. Dole VP: Fractionation of plasma nonesterified fatty acids. Proc Soc Exp Biol Med 93:532–533, 1953

41. Bligh EG, Dyer WJ: A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911–917, 1959

42. Berasi SP, Huard C, Dongmei L, Shih HH, Sun Y, Zhong W, Paulsen JE, Brown EL, Olofsson SO: Adipocyte differentiation-related protein antisense oligonucleotide. J Biol Chem 276:8401–8406, 2001

43. Brown EL, Gimeno RE, Martinez RV: Inhibition og gluconeogenesis by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. J Lipid Res 51:1029–1035, 2004

44. Listenberger LL, Ostermeyer-Fay AG, Goldberg EB, Brown DA: Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interaction with the insulin receptor and inhibits insulin action. J Biol Chem 271:649–655, 1996

45. Imai Y, Varela GM, Jackson MB, Graham MJ, Crooke RM, Ahima RS: Reduction of hepatosteatosis and lipid levels by an adipose differentiation-related protein antisense oligonucleotide. Gastroenterology 130:1947–1957, 2006

46. Wolins NE, Quaynor BK, Skinner JR, Tzekov A, Croce MA, Gropler MC, Magnusson B, Asp L, Bostrom P, Ruiz M, Stillemark-Billton P, Lindgren M, Rorsman P, Olofsson SO: Adipocyte differentiation-related protein promotes fatty acid catabolism by the ubiquitin/proteasome pathway. J Biol Chem 281:935–941, 2006

47. Magnusson B, Asp L, Bostrom P, Ruiz M, Stillmark-Billton P, Lindgren M, Rorsman P, Olofsson SO: Adipocyte differentiation-related protein modulates insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. J Mol Endocrinol 18:2024–2034, 2004

48. Berasi SP, Huard C, Dongmei L, Shih HH, Sun Y, Zhong W, Paulsen JE, Brown EL, Olofsson SO: Adipocyte differentiation-related protein antisense oligonucleotide. J Biol Chem 276:8401–8406, 2001

49. Schrauwen P, Hesselink JK: Oxidative capacity, lipidotoxicity, and mitochondrial damage in type 2 diabetes. Diabetes 53:1412–1417, 2004

50. Kershaw EE, Hamm JK, Verhaagen LA, Peroni O, Katic M, Flier JS: Adipose triglyceride lipase: function, regulation by insulin, and comparison with adiponutrin. Diabetes 56:1849–1857, 2007